Atopic dermatitis

The Lancet, Год журнала: 2025, Номер 405(10478), С. 583 - 596

Опубликована: Фев. 1, 2025

Язык: Английский

---

Topical Steroid Withdrawal Is a Targetable Excess of Mitochondrial NAD+

Journal of Investigative Dermatology, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---

How to Prevent Atopic Dermatitis (Eczema) in 2024: Theory and Evidence

The Journal of Allergy and Clinical Immunology In Practice, Год журнала: 2024, Номер 12(7), С. 1695 - 1704

Опубликована: Май 2, 2024

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease characterized by dry, itchy, and inflamed skin. We review emerging concepts clinical evidence addressing the pathogenesis prevention of AD. examine several interventions ranging from barrier enhancement strategies to probiotics, prebiotics, synbiotics; conversely, antimicrobial exposure vitamin D omega fatty acid supplementation; breastfeeding hydrolyzed formula; house dust mite avoidance immunotherapy. appraise available base within context Grades Recommendation, Assessment, Development, Evaluation approach. also contextualize our findings in relation relating AD individual-patient allergic life trajectories versus linear concept atopic march provide insights into future knowledge gaps trial design considerations that must be addressed forthcoming research. Finally, we implementation detect population-level differences risk. Major international efforts are required definitive regarding what works does not for preventing

Язык: Английский

---

Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, Год журнала: 2024, Номер 38(11), С. 2139 - 2148

Опубликована: Июль 11, 2024

Abstract Background Current treat‐to‐target recommendations for atopic dermatitis (AD) may not include high enough treatment targets and do fully consider patient needs. Objective To develop optimized AD management, including disease severity assessments, goals targets, guidance escalation/modification. Methods An international group of expert dermatologists drafted a series management using insights from global study 87 44 countries. Experts voted on modified eDelphi voting process. Results The Aiming High in Eczema/Atopic Dermatitis (AHEAD) establish novel approach to incorporating shared decision‐making concept minimal activity (MDA). Consensus (≥70% agreement) was reached all 1 round voting; strong consensus (≥90% 30/34 recommendations. In the AHEAD approach, patients select their most troublesome feature(s); clinician chooses corresponding patient‐reported measure objective measure. Treatment are chosen list ‘moderate’ ‘optimal’ with achievement defined as MDA. Conclusions Patient led development recommendations, which management. Patients were involved process used generate each recommendation. However, perspectives captured global, qualitative research that considered by experts initial drafting

Язык: Английский

---

Pharmacoequity and Biologics in the Allergy Clinic: Providing the Right Care, at the Right Time, Every Time, to Everyone

The Journal of Allergy and Clinical Immunology In Practice, Год журнала: 2024, Номер 12(5), С. 1170 - 1180

Опубликована: Март 6, 2024

Язык: Английский

---

Topical anti-inflammatory treatments for eczema: network meta-analysis

Cochrane library, Год журнала: 2024, Номер 2024(8)

Опубликована: Авг. 6, 2024

Язык: Английский

---

Serologic measurements for peanut allergy

Annals of Allergy Asthma & Immunology, Год журнала: 2024, Номер 132(6), С. 686 - 693

Опубликована: Янв. 24, 2024

Язык: Английский

---

Patient-Centered Practice Guidelines: GRADEing Evidence to Incorporate Certainty, Balance Between Benefits and Harms, Equity, Feasibility, and Cost-Effectiveness

The Journal of Allergy and Clinical Immunology In Practice, Год журнала: 2024, Номер 12(10), С. 2636 - 2643

Опубликована: Март 11, 2024

Язык: Английский

---

Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway

Cells, Год журнала: 2025, Номер 14(2), С. 83 - 83

Опубликована: Янв. 9, 2025

Cannabinoid compounds have potential as treatments for a variety of conditions, with cannabigerol (CBG) being known its anti-inflammatory properties. In this study, we investigated the effects CBG in cellular model 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis (AD). model, confirmed cytotoxicity and downregulated expression inflammatory markers CCL26, IL1B, IL6, TNF (p < 0.001). mouse clinical, histological, immunological changes were analyzed. The results showed that improved severity score, epidermal thickness, mast cell count reduced cytokines (Tslp, Il1b, Il4, Il6, Il13, Il17, Il18, Il22, Il33) by qRT-PCR Western blot modulated JAK1, JAK2, TYK2, STAT1, STAT2, STAT3, p-STAT3, STAT6, p-STAT6 0.05). Subsequently, p-IκBα, NF-κB, p-NF-κB signaling factors also 0.05), corresponding skin barrier factors. study indicate effectively alleviates AD-like symptoms suggest therapeutic agent.

Язык: Английский

---

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis

JAMA Dermatology, Год журнала: 2024, Номер 160(8), С. 856 - 856

Опубликована: Июль 17, 2024

Cendakimab selectively targets interleukin (IL)-13, a type 2 cytokine implicated in atopic dermatitis (AD) pathogenesis, by inhibiting binding to its receptors (IL13R-α1 and IL13R-α2). Proof-of-concept work AD supports using cendakimab for inflammatory diseases.

Язык: Английский

---